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ABSTRACT
Immunizations play a fundamental role in reducing the occurrence of preventable diseases in
the population. Injections related to immunization are the most frequent pain-producing medical
procedure implemented worldwide and account for nearly 12 billion injections annually (CDC,
2019; Taddio et al., 2015). These procedures are often perceived as simple but can have a
variety of complications including pain. This evidence-based practice project addressed the
following PICOT question: In college-aged students receiving immunizations (P), does the
Buzzy® device (I) when compared to non-intervention standard of care (C) effectively reduce
injection site pain (O) over a 12-week time period (T)? The Buzzy® device, which uses a
combination of vibration and cryotherapy, was used to reduce injection site pain. This project
took place at a Midwest university health center in northern Indiana, and the sample included 38
college-aged students who met the eligibility criteria and consented to participate. The primary
outcome in this project was self-reported pain level. Data were collected using a visual pain
scale and associated questionnaire; pre-intervention and post-intervention self-reported pain
levels were compared using a paired t-test to determine efficacy. The outcomes of this project
indicated a statistically significant reduction in injection site pain with use of the Buzzy® device
during intramuscular injections. Additionally, the staff at the project site have verbalized intent
for continued use of the Buzzy® in the future for needle-based procedures.
Key words: immunization, intramuscular injection, needle, pain, analgesia
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CHAPTER 1
INTRODUCTION
Background
Immunizations play a vital role in diminishing the occurrence of preventable diseases in
the general population across the globe. Because of vaccines, diseases that could have a
detrimental impact on individual life have been significantly diminished in occurrence, with
diseases like diphtheria and polio nearly eliminated (CDC, 2018). Injections related to
vaccination are the most frequent pain-producing medical procedures performed worldwide.
Among pediatric and adult patients alike, vaccinations account for nearly 12 billion injections
annually (CDC, 2019; Taddio et al., 2015).
Intramuscular (IM) injections are often assumed to be simple procedures but can have
complications. One of the most common complications associated with these injections is pain.
There is a large degree of variation in the amount of pain experienced by individuals receiving
an immunization. Common factors that affect pain associated with IM injections include anxiety,
previous poor experiences, patient position, medication volume and viscosity, chemical
composition of the drug, available solution of the drug, rate of delivery, injection technique, and
anatomic location of the injection site (Sahin & Eser, 2018).
Studies have been performed using numerous interventions to assist with injection site
pain associated with IM injections. These intervention includes z-track technique, local cold
application, manual pressure on injection site, slow injection, and topical lidocaine or other
anesthetic cream. Overall, there has been supportive data for all of these interventions, but
there is no single integrated intervention to optimize pain relief universally (Öztürk, Baykara,
Karadag, & Eyikara, 2017; Sahin & Eser, 2018; Taddio et al., 2015). Many times, patients are
fearful of injections because they perceive it will be a painful procedure. The patient then
anticipates pain, has anxiety, and this can exacerbate or negatively influence the perception of
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pain experienced during the procedure. In fact, it has been reported that up to 30.6% of patients
experience fear of injections (Sahin & Eser, 2018). With data showing this is an issue that
occurs across a variety of ages, situations, and healthcare settings, an intervention is needed to
aid in minimizing injection site pain and the associated fear.
Data from the Literature Supporting Need for the Project
The Centers for Disease Control and Prevention (CDC) recommends routine
immunization as best practice to prevent 17 vaccine-preventable diseases that occur in infants,
children, adolescents, and adults (CDC, 2019). Many individuals are exposed to needle-based
procedures throughout their lifetime, often beginning in childhood with immunizations. As
previously stated, up to 30.6% of patients experience fear of injections and pain related to a
number of factors which can negatively impact individual health and prevent future vaccination
compliance (Sahin & Eser, 2018).
There are several methods of pain management for needle-based procedures including
pharmacological and nonpharmacological. Pharmacological methods of pain control include
local topical anesthetics such as 5% lidocaine-prilocaine cream, 4% tetracaine gel, 4% lidocaine
cream, and needle-free powder lidocaine and iontophoresis. These have not been universally
accepted because of their cost and the duration of time required to take effect (a minimum of 15
minutes with a maximum of 60 minutes). Medications also have a higher risk of adverse
reactions which can complicate completion of the injection procedure. In addition to this, many
alternative interventions are not time-efficient or cost-effective, and require staff training; this
does not lend to busy healthcare settings, making the translation to consistent practice unlikely
(Canbulat et al., 2015).
It is recommended that interventions for IM injections pain relief should be as
noninvasive as possible and have the ability to be administered rapidly to improve pain control
(Yilmaz et al., 2019). Some nonpharmacological interventions meeting these criteria include
distraction techniques such as watching television and blowing bubbles (pediatrics) and music
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distraction. Also included as nonpharmacological are physical techniques such as manual
pressure and the use of a ShotBlocker® device to apply pressure at the injection site. While
these have supportive data and shown the ability to improve the level of pain individuals
experienced, no single integrated distraction technique has shown the ability to consistently
optimize pain relief (Sivri Bilgen & Balcı, 2019; Taddio et al., 2015; Yilmaz et al., 2019).
Within recent years, the Buzzy® device has come to the forefront of research as a
means of convenient, effective pain relief. The bee-shaped device combines tactile stimulation
with topical cryotherapeutic analgesia via ice-pack wings. The device acts as a
nonpharmacological method of pain relief based on the Gate Control Theory (Ballard et al.,
2019; Canbulat et al., 2015; Sahin & Eser, 2018; Sivri Bilgen & Balcı, 2019). The combination of
distracting vibration along with prolonged cold exposure at the injection site blocks nerve
impulses while disrupting the patient’s focus during the painful procedure. This device has
several advantages including ease of use, a short duration of time to see desired effects, and
the ability to easily clean and reuse the device making it more cost-effective (Bergomi et al.,
2018). The statistical evidence backing the efficacy of this device has been consistent across
the literature, with several sources that declare its efficacy in a variety of populations (Ballard et
al., 2019; Bergomi et al., 2018; Canbulat et al., 2015; Sahin & Eser, 2018; Sivri Bilgen & Balcı,
2019).
Data from the Clinical Agency Supporting Need for the Project
The facility where this evidence-based practice (EBP) project was conducted is a health
center at a private university in northern Indiana serving the faculty and student population. This
clinic is not part of a larger organization. The health center staff consists of a director, a
physician, three nurse practitioners, a registered nurse, a medical assistant, and a receptionist.
The director of the health center, a doctoral educated nurse practitioner (NP), approved the
project and served as site facilitator. All other staff agreed to participate with the medical
assistant and registered nurse agreeing to use the Buzzy® device accordingly.
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The care provided at this facility ranges in age and complexity. It offers easy access for
domestic and international college-aged students so they remain healthy and able to pursue
their education. Patients’ age ranges vary with the vast majority being 18 years of age and
higher. The comprehensive services offered are similar to that of any other family practice clinic
and provides access to specialties via referral. As of fall semester 2020, campus has mandated
both the meningococcal B and influenza vaccines for the student body. A method of pain relief
with IM injections is present within this facility which will vaccinate nearly 4,000 students and
staff members (Site Facilitator, personal communication, July 3, 2020).
The student body that this health center serves is 68.9% White, 10.1% Hispanic or
Latino, 5.3% Black, 6.5% non-domestic international students, 2.3% Asian, 0.1% American
Indian, 0.1% Native Hawaiian or other Pacific Islander, and the remaining 7.7% identifying as
more than one ethnicity or one that was not listed. As of fall 2019, only 7.3% of students were
registered as part-time; the remaining 92.7% were registered as full-time students (University in
Northern Indiana, 2019).
The town where this EBP project was located is in the northern part of Indiana and has a
population of 35,501 people. The poverty rate is 13.6% and the median household income is
$52,507 annually. The race and ethnicity statistics are as follows: 86.4% White, 3.06% Black or
African American, 2.48% Asian, 0.83% two or more races, 0.25% American Indiana or Alaska
Native, 0.17% Native Hawaiian or other Pacific Islander, and 0.47% other (Data USA, 2017).
Purpose of the Evidence-Based Practice Project
The purpose of this EBP project was to reduce the amount of pain experienced with IM
injections in college-aged students. The literature supports a need for holistic care approaches
for individuals with needle fear through physical and psychological components during needlebased procedures such as immunizations. By using an evidence-based intervention for this EBP
project, the incorporation of a systemic search of the literature, and assimilation of critically
appraised research this allows to work towards goal achievement of vaccination injection site
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pain reduction. Reaching this goal provides for not only IM injection pain relief, but improving the
individual’s overall experience and future adherence to healthcare.
PICOT Question
This evidence-based practice project will address the following PICOT question: In
college-aged students receiving immunizations (P), does the Buzzy® device (I) when compared
to non-intervention standard of care (C) effectively reduce injection site pain (O) over a 12-week
time period (T)?
Significance of the EBP Project
The fear of needles or in severe cases, needle phobia, typically begins at a young age
and can carry through to adulthood. Fear of needles contributes to a variety of notable, harmful
consequences such as vaccination noncompliance and avoidance of health care. Additionally,
needle fear is a known contributor to vaccination hesitance, making the alleviation of injection
site pain a public health issue that can have a significant impact (McMurtry et al., 2015). The
Buzzy® device has been shown to have statistically significant results in diminishing injection
site pain in both children and adults (Sahin & Eser, 2018; Canbulat, Ayhan, & Inal, 2015; Tadio
et al., 2015). By using a nonpharmacological intervention based on the Gate Control Theory,
pain can be diminished without the associated risks of using another chemical substance and
considers the practicality of time efficiency (Canbulat, Ayhan, & Inal, 2015). Assuaging injection
site pain in adults and children can aid in the promotion of future vaccination compliance and
have a meaningful, positive impact on individual’s perception of health care. Lastly, it has
important indications for public health as a whole by facilitating the empowerment of individuals
to receive recommended routine vaccinations and further global efforts to diminish preventable
diseases.
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CHAPTER 2
EBP MODEL AND REVIEW OF LITERATURE
Evidence-based Practice Model
A variety of evidence-based practice models were reviewed and analyzed to determine
the best fit for application to this project. After a thorough evaluation, the Johns Hopkins Nursing
Evidence-Based Practice Model (JHNEBPM) was selected as a guide for project development
and implementation. This model was created specifically to transition EBP into the clinical
setting for clinical, educational, and operational practice (Melnyk & Fineout-Overholt, 2019).
Overview of EBP Model
The JHNEBPM model was initiated in 2002 after a gap was recognized in the standard
of nursing practice by the organizational leadership at Johns Hopkins Hospital (JHH). The
deficiency was in the translation of research to practice. A team was formulated with the
endeavor of accelerating the conversion of best practice research principles for nurses to
practice in both the clinical setting and at bedside (Melnyk & Fineout-Overholt, 2019).
By including nurses as key stakeholders in the development and piloting of this model, it
ensured that the model would be formulated with nursing feedback and evaluation. The
construction of the JHNEBPM allowed for a clear delineation of the EBP process, with mentored
steps and tools to accompany each phase of the process. When using the model, a person
starts by formulating an inquiry related to best practice about a clinical problem. The next step is
initiating the practice question, evidence, and translation (PET) process. The PET process is the
core of the JHNEBPM, with 19 steps outlined among the three phases. The steps begin with the
recruitment process of an interprofessional team and progress through dissemination of findings
(Melnyk & Fineout-Overholt, 2019).
The first phase, practice question, prioritizes the recruitment of an interprofessional team
and the refinement and defining of the clinical problem and EBP question. Key stakeholders are
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identified, responsibility of project leadership is determined, and a schedule of team meetings is
completed. During the evidence phase, an internal and external search for evidence is
performed. Appraisal of the evidence is achieved to determine its level and quality. The
evidence is then summarized and a synthesis of the findings, quality, and strength is generated.
Next, recommendations for changes in practice are developed based on the body of literature
and evidence synthesis. During the final phase, translation, recommendations are analyzed to
determine fit, feasibility, and appropriateness. Once this occurs, the project leader can create an
action plan, secure support and resources for implementation, implement the action plan,
appropriately evaluate outcomes, report findings and outcomes to stakeholders, identify next
steps, and disseminate the findings (Dang & Dearholt, 2017).
Application of EBP Model to DNP Project
This model is particularly useful as it acknowledges internal and external factors and
how they influence the process of problem-solving and clinical decision making, which
incorporates participation from a variety of key stakeholders (Dang & Dearholt, 2017). This is an
essential part of any EBP project, especially with the setting for this EBP project being
performed at a university. The considerations in this setting include the impact of external
factors on schools, academic calendars, and a higher level of inquiry from parents and other
associated stakeholders.
The 19-step process outlined in the JHNEBPM across three phases was used for the
planning, development, implementation, and translation of the Buzzy® device into practice. In
the first phase, a practice question was raised regarding the best practice for reducing injection
site pain in college-age students receiving IM injections. Key stakeholders at the practice
included a physician, three NPs, a registered nurse, and a medical assistant. Other key
stakeholders included participants and their families. Evidence regarding the efficacy and
usefulness of the Buzzy® device was discussed with stakeholders and identified as being
helpful for college-age students being seen in the health center for IM injections. The Buzzy®
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device was selected for implementation because it met the needs outlined by the initial gap in
practice and addressed the practice question with supported evidence from the literature.
Strengths and Limitations of EBP Model for DNP Project
When assessing the usefulness and applicability of the JHNEBPM, a number of
strengths and weaknesses were identified. A strength of the model is its creation for nurses to
translate research into best practice in the clinical setting. By using it as a guide for an EBP
project in a doctoral level nursing program, a certain level of continuity can be achieved. Both
the end goal of the project and the model are the same because they identify and implement
best practice in a way that applies to nurses, clinicians, and other medical professionals. In
addition to this, the model integrates multiple noteworthy facets into this translation such as
education, current practice, research, and practicality. This allows for the model to provide a
best practice recommendation which is approachable and versatile guiding a change in practice.
Also, it provides support for the implemented practice to be practical and sustainable for longterm inpatient and outpatient settings.
An added strength of the JHNEBPM is its recognition of the value of non-research data.
A well-rounded, comprehensive look at the literature can be achieved and less tangible
variables can be considered because this model excludes scales to assess expert opinion and
valuable qualitative data (Melnyk & Fineout-Overholt, 2019). Finally, the JHNEBPM is structured
in a way that allows the researcher or project leader to introduce new questions throughout the
project. The structure allows for new EBP processes to be initiated without interrupting the cycle
of inquiry, evidence-gathering, and dissemination. This type of open system contributes to the
development of best practice by encouraging the pursuit of relevant and influential information
without disrupting the ultimate ambition of best practice.
Limitations of the JHNEBPM are present, and one of them can be extracted from its
strengths. Even though the model clearly delineates steps of the EBP process, the 19 steps
associated with the three phases make it detailed and can appear complex. For a novice project

9

DON’T BE SUCH A BUZZY®KILL
leader, these steps are extremely helpful in guiding an effective project, but to an expert the 19
steps may be deemed excessive or constricting to the EBP process.
Literature Search
Sources Examined for Relevant Evidence
The literature review for this project initiated in the Joanna Briggs Institute (JBI) and
Cochrane Library databases. These were selected initially because they tend to offer high level
and quality evidence guiding best practice for setting new standards of care. Relevancy for this

literature search was determined via inclusion and exclusion criteria which included strategies to
decrease injection site pain with needle-based procedures and excluded pain relief with needlebased procedures where the primary cause of pain was not at the injection site (i.e. lumbar
puncture). Additionally, nonpharmacological methods were preferred not required, and the
method had to transfer to the adolescent or young adult population in the primary care setting.
JBI was the first database searched for quality systematic reviews, using key terms
immunization AND pain. The limiters used in this database for the search included evidence
published within the last five years. This search yielded 32 results, of which five were relevant
but were evidence summaries or protocols and were ultimately excluded. Another search was
performed using the terms intramuscular injection AND pain. This search yielded 25 results, of
which eight were relevant. These included evidence summaries and protocols, along with one
systematic review. Citation chasing resulted in three useful articles also found in Medline with
Full Text. Ultimately, the systematic review was excluded because the reported confidence in
the evidence was low.
The next database searched was Cochrane Library. Initial key terms searched included
“intramuscular injection*” AND pain*. Limiters included publication between January 2015 and
June 2020 and English language. With these key terms, there were 22 results, and none were
relevant. To make a more accurate search, key terms were modified to immunization OR needle
AND pain* OR analgesia. The limiters of publication between January 2015 and June 2020
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were used, along with English language. There were 125 results, of which eight were relevant.
Ultimately, these were excluded because seven applied to specific pediatric populations such as
newborns or children undergoing specific treatment and involved interventions not transferable
to the adolescent and young adult population. The eighth result was excluded because the
recommended intervention could not be practically applied to the primary care setting. An
additional search was performed in Cochrane using the key terms needle AND pain. This
search yielded 86 results, four of which were relevant to pain relief with IM injections but were
excluded as the interventions assessed were not relevant to the project‘s population.
After Cochrane Library was thoroughly explored, the Trip database was searched. This
database is known to be useful in finding established clinical practice guidelines from various
reputable organizations in medicine. The key search terms used for the best search were
“intramuscular injection*” AND pain*. The limiters used in this database included evidence
published within the last five years and USA guidelines. From this search, there were 21 results,
of which none were relevant based on the aforementioned criteria.
The literature search continued in Medline with Full Text. Best search key words
included “intramuscular injection*” OR “IM injection*” AND pain* AND adult* OR adolescen*.
Limiters used in the search included evidence published within the last five years, English
language, and Scholarly (Peer Reviewed) Journals. This search yielded 157 results, 21 of which
were relevant and three duplicates which were found through citation chasing in JBI. An
additional search was performed with the same previous key terms and limiters, plus “needle
insertion.” This search yielded 175 results, but none of the new pieces of evidence were found
to be relevant.
After a comprehensive search of Medline with Full Text, a search was performed in
CINAHL. The initial search included key terms “intramuscular injection” OR “IM injection” AND
pain OR “pain reduc*” OR “pain relief” OR “pain manag*” AND adult* with limiters including
evidence published in the last five years, English language, and Scholarly (Peer Reviewed)
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Journals. The search came up with 53 results, but was refined to include key terms and
truncation symbols “intramuscular injection*” OR “IM Injection*” AND pain* AND adult* OR
adolescen* with the same limiters previously mentioned. This search yielded 76 results, 14 of
which were relevant and five of which were duplicates of articles found within Medline with Full
Text.
Once the majority of articles were found, references were reviewed to ensure saturation
had been achieved and all sources had been exhausted. Through citation chasing, three articles
were found which were included within this project. One was through an article found in Medline
with Full text, and the other two were found via ValpoScholar in another evidence-based
practice project titled What’s all the Buzzy® about? Using Cryotherapy and Vibration for Pain
During Vaccinations in Children. After going through the references to ensure saturation, two
more articles were found and included. Additionally, a hand search was done on the Buzzy®
website, which gives access to a variety of articles with supporting evidence for this device. The
studies that met the inclusion and exclusion criteria had already been found in other databases.
The summary of selected data for this project can be referenced in Table 2.1.
Levels of Evidence
The evidence leveling and appraisal tools selected for this project were the Johns
Hopkins Nursing Evidence-Based Practice (JNHEBP) research appraisal tools. These tools
provide the user the ability to both level the evidence and determine the quality with established
criteria to minimize error due to subjectivity. For example, when appraising randomized
controlled trials (RCTs) or systematic reviews, there are three questions asked of the appraiser.
If the answer to all three questions is “yes,” then the article is determined to be level I, or the
highest level of evidence.
The majority of the selected evidence for this project comprises of level I and level II
evidence. One piece of evidence was level IV according to the JNHEBP research appraisal
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Table 2.1
Evidence Search Table
Database

Yielded

Duplicates

Reviewed

Accepted

JBI

25

0

8

1

Cochrane

125

0

4

0

Trip

21

0

0

0

Medline

157

3

21

5

CINAHL

76

5

14

1

Citation Chasing

8

0

6

3

Total

412

8

53

10
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tools. This was included because it offers clinical practice guidelines relevant to this project and
is categorized as level IV because it qualifies as expert opinion.
Appraisal of Relevant Evidence
The quality of the evidence (high, good, or poor; Grades A, B, or C, respectively),
according to JHNEBP, is determined by whether the results were consistent or generalizable, a
sufficient sample size was present, consideration of the study design, if there was adequate
control, and the quality and comprehensiveness of the literature review done prior to initiating
the study that indicates consistent recommendations (Dang & Dearholt, 2017). The tool asks the
appraiser 12-15 questions dependent on the type of evidence being appraised in order to simply
and logically level as well as appraise the evidence.
Depending on the appraiser’s answers to the questions within the tool, certain
conclusions can be drawn. There is a level of subjectivity and critical thinking on the part of the
appraiser that can result in variability due to opinion. All evidence used for this project was
determined to be of Grade A (high) or Grade B (good) quality. Table 2.2 summarizes included
evidence for this EBP project.
Level I Evidence
Ballard et al. (2019). This article is a systematic review and meta-analysis published by
Ballard et al. (2019) discussing the efficacy of the use of the Buzzy® device for pain relief in
various needle-based procedures. For this systematic review, a systematic literature search was
performed in databases including PubMed, Ovid MELINE, Ovid All EBM Reviews, Ovid Embase
and Ovid PsycINFO, and Allied Health Literature (CINAHL) from the date of project initiation
until December 18, 2017. Searches were completed with the assistance of a research librarian
and with a tailored search for each database. Specific inclusion and exclusion criteria were
implemented to include only RCTs that compared the Buzzy® device to a control group of
infants, toddlers, children, and adolescents. The age range of participants in the included
studies were determined by the following criteria, including individuals between 28 days and 18
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years of age requiring a needle-based procedure. Needle-based procedures encompassed in
this systematic review included immunizations, venipuncture, IV insertion, and IM or
subcutaneous injections. Additionally, the systematic review included RCTs that assessed
combination cold and vibration therapy. There was not a language restriction set on the
literature search. Based on the inclusion and exclusion criteria, nine RCTs were included in the
systematic review; seven of these were included in the meta-analysis.
From the nine selected studies, a total of 1,145 participants aged 3 to 18 years from
2011 to 2018 were included. Control groups compared to the Buzzy® device had an absent or
nonpharmacological intervention, no intervention, vapocoolant spray or topical anesthetic, or
distraction cards. Needle-based procedures across the studies included three with IV insertions,
two with venipunctures, two with IV and venipunctures, and two with immunizations. The
primary outcome measured was needle-related procedural pain intensity. This was evaluated
either during or immediately after the procedure by self-reported pain via selected pain scale,
parent-reported pain, or observer-reported pain. All selected self-reported pain scales were
validated for use in the selected population. Statistical analyses showed a statistically significant
effectiveness in pain reduction with the Buzzy® device. There was a reported SMD –1.12; 95%
CI: -1.53 to -0.71 where p < 0.0001. By the JHNEBP tool criteria, this systematic review was
deemed level I, Grade A quality.
Bergomi, Scudeller, Pintaldi, & Dal Molin (2018). A RCT was conducted to compare
efficacies between topical cryotherapeutic analgesia (Buzzy®) and animated cartoons as a
distraction technique in reducing pain and anxiety in children undergoing venipuncture. The
sample included children between the ages of 5 and 12 years, with a total of 150 participants.
These participants were randomized into four groups: Buzzy® only, distraction via cartoons and
Buzzy®, distraction via cartoons alone, and no intervention. Randomization was performed by
an independent statistician through the RALLOC method in Strata® 13 using blocks. A number
of opaque sealed envelopes were prepared to include the allocated groups and dispersed to the
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appropriate participants and locations. All pain and anxiety scales used in the study were
explained to parents and children prior to participation, with an emphasis that the primary
outcome measure was pain. Secondary outcomes included parents’ and nurses’ perception of
the child’s pain and anxiety. Within the study, both primary and secondary outcomes measuring
the child’s pain utilized the Wong-Baker Faces Pain rating scale (WBFC). The Children’s
Emotional Manifestation Scale was used to determine the perception of the child’s anxiety.
Parental anxiety was measured using the Numeric Rating Scale and by asking them to estimate
their own level of anxiety on a scale of 0 to 10.
Statistical analysis comparing the four groups was performed by way of one-way
analysis of variance. Categorical variables were compared by way of the Pearson’s c2 test; a pvalue of <0.05 was considered to be statistically significant. The Strata computer software was
used to run the data. Results of the secondary analysis showed that the Buzzy® device was
highly effective in children under the age of 9 (p = 0.04). Additionally, a significant efficacy was
found in the Buzzy® and animated cartoon group (p = 0.04) for the nurse’s perception of the
child’s pain, and in the Buzzy® group for the mother’s perception of the child’s pain (p = 0.002).
Based on the JHNEBP tool, this study is categorized as level I and was determined to be Grade
A quality.
Canbulat, Ayhan, & Inal (2015). A RCT was performed to assess the ability of the
Buzzy® device to reduce pain and anxiety in children undergoing peripheral intravenous
cannulation. The sample for this study included children aged 7 to 12 years who required
peripheral IV cannulation. Participants were excluded from the study if there was an abrasion
where the device would be placed, if there was nerve damage on the affected extremity, critical
or chronic illness lending toward poor health, neurodevelopmental delays, difficulties with verbal
communication, use of an analgesic within the last 6 hours, or history of syncope due to blood
specimen collection or immunization. Additionally, none of the participants had previous
experience with peripheral IV cannulation.
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A total of 176 children and their parents consented to participate and were randomly
assigned to the intervention group (cold and vibration Buzzy® therapy) or the control group (no
intervention). To assess pain, the child self-reported pain via the WBFC and the Visual Analog
Scale (VAS) immediately post-cannulation procedure. To analyze the data, Statistical Package
for the Social Sciences (SPSS) version 15.00 was utilized where p < 0.05 was considered
significant. Reported pain and anxiety levels in children were compared with the Student’s t test.
Nonparametric data, including sex and parental education levels, were compared with
frequency testing and χ². When pain and anxiety levels were compared with an independent t
test, the children in the external cold and vibration group experienced significantly lower pain
levels than the control group based on their self-reported pain (both WBFC and VAS scores
where p < 0.001). Using the JHNEBP tools, this article was categorized as level I, Grade A
evidence.
Sahin & Eser (2018). A RCT was performed with the purpose of determining the effect
of the Buzzy® device on injection site pain and satisfaction with injection experience in adults.
To ensure the study was single-blind, evaluation of pain and satisfaction via VAS was carried
out by another nurse who was educated beforehand on using the scale. For this study,
participants were randomly assigned by age and gender into an intervention group (with the
Buzzy®) and a control group (no intervention). Each participant received only one injection,
which was given by the researcher to avoid any factors that could affect outcomes related to
changing injectors. Evaluation of pain and satisfaction was performed by the nurse to ensure
impartiality. The study sample consisted of 65 individuals who received IM injections of
diclofenac sodium into the ventrogluteal site in the physical therapy department of a state
hospital from November 2012 to January 2013. To be included, patients met the following
criteria: have not had an IM injection within the last seven days; no complaints related to an IM
injection-related complication such as pain at the injection site, abscess, infection, tissue
necrosis, or hematoma; being conscious with no problems with communicating, vision, or
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hearing deficits; between ages 25 and 85; accurate use of the VAS pain rating tool. One VAS
tool was used immediately post-injection to rate pain levels. The second VAS tool was used for
a satisfaction assessment.
Data was assessed using SPSS version 20.0. A χ² test was performed to assess
homogeneity between the groups and the distribution of distinguishing patient characteristics.
To make comparisons between the groups in regards to pain and anxiety, the Mann-Whitney U
test was performed. Ultimately, results showed post-injection mean pain scores in application
group of 4.67 ± 4.94 and pain post-injection mean pain score in control group of 17.69 ± 9.85.
Injection satisfaction mean scores in the application group were 94.82 ± 4.97, and injection
satisfaction mean scores in the control group were 85.06 ±13.39. In the application group, post
injection pain was significantly lower and injection satisfaction significantly higher than in the
control group. This piece of evidence was determined to be level I, Grade A by the JHNEBP tool
criteria.
Sivri Bilgen & Balcı (2019). A RCT was performed to assess and compare the
efficacies of the Buzzy® device and the ShotBlocker® device on reducing pain with IM
injections of penicillin in children. A power analysis was performed using the Power (v3.1.7)
program to determine the appropriate sample size, a minimum of 48 individuals per group. The
number was increased to 50 per group to account for participant losses. To ensure
randomization, numbers from 1 to 150 were divided randomly into three groups using a
computer-based program without number repetition. Participants were randomly assigned to
their appropriate group: Buzzy® device, ShotBlocker® device, and control group. Parents and
their children were informed about the procedures, and their written and verbal consent was
obtained prior to participation. During a face-to-face interview with the researcher, an
information form was completed with parents and children. Outcomes were measured using the
Visual Analog Scale and Faces Pain Scale-Revised (FPS-R) to evaluate pain at one minute and
five minutes post-injection. State-trait anxiety inventory for children (STAIC) prior to the
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procedure was also measured to determine anxiety levels and identify significant differences
between each group.
Data was measured using the SPSS for Windows, version 22 and the Number Cruncher
Statistical System (NCSS) 2007 program for statistical analyses. Data from the study utilized the
one-way analysis of variance and dependent samples t-test in those showing a normal
distribution. In those without a normal distribution, a Kruskal-Wallis, Person’s, and chi-square
test was performed. The value of p < 0.001, Buzzy® showed the most statistically significant
results in pain reduction and post injection satisfaction in children. Additionally, there was no
significant statistical difference between the mean scores of the STAIC among groups before
the procedure. Based on the JHNEBP tool criteria, this piece of evidence was determined to be
level I, Grade A quality.
Yilmaz & Alemdar (2019). A RCT was performed to compare usefulness of the Buzzy®
device, the ShotBlocker® device, and bubble blowing as distraction in children receiving
intramuscular injections. The study sample included children ages 5 to 10 years undergoing
intramuscular injection, as well as their parents. The inclusion criteria included children between
the ages of 5 and 10 years who were patients in a pediatric emergency department receiving IM
injections. Additionally, it was imperative that children were accompanied by parents or family
members. Participants were excluded if they had received local anesthetics; if there was a skin
infection or pathology at the site of injection; if there were diseases or significant trauma
requiring immediate attention; showed signs of developmental delay; had chronic illnesses; had
altered sensorium or neurosensory deficit at the site of injection; or if developmental delay
prevented completion of the pain scale. To determine sample size, G*Power (v3.1.9.2) was
utilized. The approximate number of participants was calculated to be 40 according to Cohen’s
effect size coefficients. Children were placed randomly according to a computer program into
four subgroups: Buzzy® device, ShotBlocker® device, bubble blowing, and no intervention. The
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primary outcome measured was pain and the secondary outcome measured was fear.
Instruments used to measure these outcomes included interview forms, procedural fear
(Children’s Fear Scale [CFS]), and self-reported pain scores via Oucher pain scale.
Statistical analysis was completed using SPSS for MS Windows XP. The Shapiro-Wilk
test was used to assess distribution of the data. Additionally, comparisons of procedural fear
(CFS scores) and pain (Oucher scores) was completed using a one-way analysis of variance
(ANOVA) and the post hoc advanced analysis Bonferroni test for binary comparison was used
for statistical analyses. Results showed that where p < 0.05, ShotBlocker®, Buzzy®, and
bubble-blowing were all effective in reducing fear, with Buzzy® being the most effective. This
study was determined to be level I, Grade A quality by the JHNEBP criteria.
Level II Evidence
Öztürk, Baykara, Karadag, & Eyikara (2017). A comparative experimental study was
performed to determine the usefulness of applying manual pressure to the deltoid injection site
for pain reduction during intramuscular injections of the hepatitis A and hepatitis B vaccinations
in college students. The sample consisted of 123 first-year university students scheduled to
receive their hepatitis A and hepatitis B vaccinations in the deltoid injection site. Students were
assigned randomly to either a comparison group, who was given standard of care, or an
experimental group, which received manual pressure at the injection site immediately prior to
the injection for 10 seconds. A self-administered questionnaire comprised of two components
was completed by each participant for data collection. The first component collected
demographic data, and the second included a Numeric Rating Scale (NRS) for pain rating. The
NRS was used to determine perceived pain just before injection and immediately post-injection
by the student. Pain levels were also obtained by an independent specialist nurse who did not
witness the injection. Using the NRS, the students indicated their pain level within two minutes
of the procedure. To promote uniformity in manual pressure application, a dolorimeter was used
to measure manual pressure with the investigator’s right thumb prior to the study. It was
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determined that the investigator would apply pressure with the right thumb as much as she
could until the nail bed turned white.
Data was evaluated using SPSS 17.0 software. Due to abnormal distribution of the data,
a Mann-Whitney U-test was used. When dependence between variables was evaluated, the chisquare test was utilized. The mean pain level of the experimental group after injection group
was 3.17, and in the comparison group it was 3.78 on the NRS. This showed statistical
significance where p < 0.05, indicating that manual pressure at the injection site was effective in
reducing pain in young adult students receiving intramuscular injections. By the JHNEBP tool
criteria, this piece of evidence was categorized as level II, Grade B evidence.
Şanlialp Zeyrek, Takmak, Kurban, & Arslan (2019). A systematic review and metaanalysis were performed to determine the efficacy of various physical-procedural interventions
during intramuscular injections in adults. The following databases were used for searches from
inception to November 2017: Cochrane, SCOPUS, Medline (OVID, Ebsco), and Science Direct.
Additionally, the reference lists of the received articles were searched for relevant evidence. The
search strategy was adapted for electronic databases and included key terms intramuscular
injection*, pain, randomize*, trial, and experimental. Abstracts titles were scanned by two
authors to determine full-text inclusion and appraised for suitability. The inclusion criteria
comprised of patients administered IM injections in any setting; patients were over the age of
18; physical-procedural interventions for reducing pain were used during the IM injection; RCT
or quasi-experimental study design where the effect of any physical procedural intervention at
the IM injection was examined; outcomes were related to pain at the injection site; full-text
studies were accessible; and studies were written in the English language. Exclusion criteria
removed evidence without physical-procedural intervention, where data collection was not
possible, and specific information about the method was not provided.
In total, 15 articles were included: nine were RCTs and six were quasi-experimental. The
total number of participants was 1,174 individuals aged 18 and older. The primary outcome
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measure was pain, and the measurement scales used included the NRS, VAS, and verbal
rating scale (VRS). Results found that all of the physical-procedural interventions reduced
injection pain at a moderate level. Their results also discovered it was difficult to conclude a
single intervention or method reduces pain in adults. The most effective methods were Ztechnique, manual pressure, two-needle technique, post-injection massage, and ShotBlocker®.
By the JHNEBP tool criteria, this systematic review was determined to be level II, Grade A
quality.
Taddio et al. (2015). A systematic review of RCTs and quasi-randomized controlled
trials was performed to evaluate a variety of procedural and physical interventions and their
effect on pain levels during vaccinations in a number of different age groups. A search strategy
was developed with assistance from a research librarian and performed in EMBASE, Medline,
PsycINFO, CINAHL, and ProQuest Dissertations & Theses Global. Studies were included if they
looked at individuals of all ages undergoing vaccination or the closest related skin-breaking
procedure or context (such as venipuncture) and were RCTs or quasi-randomized study
designs. A total of 31 studies were included: 24 included children, 4 included adults, and 3
included adults and children. The total number of participants was 11,880.
Critical outcomes measured included pain, distress, and fear utilizing a variety of tools
based on age and study. Interventions with a statistical significance indicating pain reduction
included no aspiration, injecting most painful vaccine last, simultaneous injections, vastus
lateralis injection, positioning interventions, non-nutritive sucking, external vibrating device with
cold (Buzzy® device), and muscle tension. The results for Buzzy® use in children ages 3 to 17
years were as follows: SMD –1.23; 95% CI: -1.58, -0.87. By the criteria in the JHNEBP evidence
leveling and appraisal tools, this systematic review is categorized as level II, Grade B quality.
Level IV Evidence
Stephenson (2019). This evidence summary and best practice recommendation was
selected to include an expert opinion about the topic in addition to the high-level pieces of
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evidence listed above. The purpose of this summary was to answer the clinical question, “What
is the best available evidence regarding strategies to reduce pain associated with intramuscular
injections?” This evidence summary comes from the following pieces of evidence: a RCT with
60 participants, 30 receiving IM injection in the ventrogluteal site and 30 in the dorsogluteal site;
a RCT with 75 participants who each received three randomized injection techniques; a RCT
with 123 participants, 63 randomized to the experimental group and 60 to the control group; a
quasi-experimental study with 48 participants; a systematic review and network meta-analysis
including 23 RCTs; and a RCT with 65 participants.
Results of the studies for the best practice recommendation established there were
several strategies utilized successfully to reduce pain associated with IM injections. These
included the air-lock technique, Z-track technique, manual pressure, manual acupressure,
topical anesthetics such as lidocaine or EMLA cream, and the Buzzy® device for cryotherapy
and tactile stimulation. The evidence recommends the use of clinical judgment and taking
patient preference into account. It does not recommend one strategy over the other. The
JHNEBP tools categorize this piece of evidence as level IV, Grade A evidence (Table 2.2).
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Table 2.2
Evidence Summary Table
Author(s)

Purpose

Design

Ballard, A., Khadra,
C., Adler, S, Trottier,
E. D., & Le May, S.
(2019).

The aim of this
systematic
review was to
analyze the
efficacy of the
Buzzy® device
on pain and
anxiety in
multiple RCTs.

Systematic
Review

Bergomi, P.,
Scudeller, L., Pintaldi,
S., & Dal Molin, A.
(2018).

To evaluate the
efficacy of two
interventions on
pain with
venipuncture in
children:
vibration with
cryotherapeutic
topical analgesia
(Buzzy®)
and distraction
by means of
animated
cartoon.

RCT

Sample
The sample
consisted of 1145
children aged 28
days to 18 years
from 9 RCTs.

Measurement/
Outcomes

Multimodal; a
variety of pain
scales were
used from the 9
RCTs to
measure
Buzzy® effect
on pain, and 7
of the RCTs
were used in
the metaanalysis.
Sample consisted Outcome
of 150 children
measures
between the ages included pain
of 5 and 12 years. perception with
Buzzy®
device alone,
animated
cartoon
distraction
alone, and
animated
cartoon with
Buzzy®. Pain
perception was
determined with
the WBFC.

Results/Findings

Level/
Quality

Overall effect of Buzzy® device
on self-reported pain was
significant: SMD –1.12; 95% CI: 1.53 to -0.71; p <0.0001

Level I
Grade
A

The secondary analysis showed
Level I
that the Buzzy® device was
Grade
highly effective in children under
A
the age of 9 (p = 0.04).
Additionally, a significant efficacy
was found in the Buzzy® and
animated cartoon group (p =
0.04) for the nurse’s perception of
the child’s pain, and in the
Buzzy® group for the mother’s
perception of the child’s pain (p =
0.002).
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Canbulat, N., Ayhan,
F., & Inal, S. (2015).

The purpose of
this study was to
determine the
effect of the
Buzzy® device
on pain and
anxiety levels of
children during
peripheral IV
cannulation.

RCT

Öztürk, D., Baykara,
Z. G., Karadag, A., &
Eyikara, E. (2017).

The purpose of
this study was to
determine the
efficacy of
manual pressure
at the deltoid
injection site in
decreasing
injection site
pain in young
adult students
receiving the
hepatitis A and
hepatitis B
vaccines.

Comparative
experimental
study

To determine
the effect of the
Buzzy®
device on
injection site

RCT (Singleblind,
randomized,
prospective
design)

Şahin, M., & Eşer, İ.
(2018).

The sample
included 176
children between
7-12 years of age
randomly
assigned to a
control group with
no intervention
and an
experimental
group receiving
treatment with
Buzzy® device.
Sample consisted
of 123 students;
60 students were
in the comparison
group and given
standard of care
and 63 students
were in the
experimental
group, receiving
manual pressure
at the injection
site for 10
seconds before
the injection.

Outcomes
measured
included pain,
measured with
the WBFC and
VAS. Anxiety
was also
measured using
the CFS.

When pain and anxiety levels
were compared with an
independent t test, the children in
the external cold and vibration
group experienced significantly
lower pain levels than the control
group based on their selfreported pain (both WBFC and
VAS scores where p < 0.001).

Level I
Grade
A

Outcome
measures
included pain
levels using the
NRS. Pain
levels were
taken by an
independent
specialist nurse
who did not
witness the
injection. Using
this scale, the
students
indicated their
pain level within
two minutes of
the procedure.
65 individuals
Pain: measured
who received IM
with the VAS.
injections of
The first VAS
diclofenac sodium was used to
evaluate pain

The mean pain level of the
experimental group after injection
group was 3.17, and in the
comparison group it was 3.78 on
the NRS. This showed statistical
significance where p < 0.05,
indicating that manual pressure
at the injection site was effective
in reducing pain in young adult
students.

Level II
Grade
B

Post injection mean pain score in
application group: 4.67 ± 4.94
Post injection mean pain score in
control group: 17.69 ± 9.85

Level I
Grade
A
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pain and
resulting
satisfaction with
injection
experience.

Şanlialp Zeyrek, A.,
Takmak, Ş., Kurban,
N. K., & Arslan, S.
(2019).

The purpose of
this systematic
review was to
determine the
efficacy of
various physicalprocedural
interventions
during
intramuscular
injections in
adults.

Systematic
Review

and ranged from
after injection
ages 25-85 years. ranging from
“no pain” to,
“unbearable
pain.” The
second VAS
was used to
determine
satisfaction with
a range from
“I’m very
satisfied” to, “
I’m not satisfied
at all.” Both of
the VAS were
on a vertical line
100 mm long.
The sample
The primary
included 15
outcome
articles; 9 were
measured was
RCTs and 6 were pain. Scales
quasiused to
experimental
measure pain
studies. The
included the
number of
NRS, VAS, and
participants
VRS.
totaled 1,174
adults aged 18
and over.

Injection satisfaction mean score
application group: 94.82 ± 4.97
Injection satisfaction mean score
control group: 85.06 ±13.39
In the application group, post
injection pain was significantly
lower and injection satisfaction
significantly higher than in the
control group.

Results found that all of the
physical-procedural interventions
reduced injection pain at a
moderate level, and that it was
difficult to conclude that a single
intervention or method reduces
pain in adults. The most effective
methods were Z-technique,
manual pressure, two-needle
technique, post-injection
massage, and ShotBlocker®.
Z- technique (SMD = 0.563, 95%
CI = 0.216–0.909, p = .001)
Manual pressure (SMD = 0.523,
95% CI = 0.193–0.853, p = .002)

Level II
Grade
A
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Two-needle technique (SMD =
0.744, 95% CI = 0.335–1.154, p
= .001)
Post-injection massage (SMD =
1.818, 95% CI = 1.076–2.561, p
= .001)

ShotBlocker: (SMD = 1.021, 95%
CI = 0.468–1.574, p = .001)
Sivri Bilgen, B., &
Balcı, S. (2019).

The purpose of
this study is to
determine the
efficacy of both
the Buzzy® and
ShotBlocker® in
reducing pain
with
intramuscular
injections in
children.

RCT

The sample
consisted of 150
children ages 712 divided equally
into three
subgroups:
Buzzy® group,
ShotBlocker®
group, and
control group.

Outcomes were
measured using
the VAS and
FPS-R to
evaluate pain at
one minute and
five minutes
post-injection.
STAIC prior to
the procedure
was also
measured to
determine
anxiety levels
and identify
significant
differences
between each
group.

VAS (1st minute) where p <
0.001:
ShotBlocker®: 6.36 ± 3.24
Buzzy®: 3.68 ± 3.05
Control: 7.34 ± 3.11
VAS (5th minute) where p <
0.001:
ShotBlocker®: 3.38 ± 2.94
Buzzy®: 1.68 ± 2.28
Control: 4.88 ± 3.24
FPS-R (1st minute) where p <
0.001:
ShotBlocker®: 6.24 ± 3.20
Buzzy®: 3.64 ± 3.10
Control: 7.36 ± 3.09
FPS-R (5th minute) where p <
0.001:
ShotBlocker®: 3.24 ± 2.96
Buzzy®: 1.52 ± 2.23
Control: 4.84 ± 3.29

Level I
Grade
A
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Buzzy® showed the most
statistically significant results in
pain reduction and post injection
satisfaction in children.
There was no significant
difference between the mean
scores of STAIC before the
procedure (ShotBlocker®=38.50±5.47;
Buzzy®=37.74±6.07;
control=40.16±6.24
Stephenson, M.
(2019).

The purpose of
this JBI
evidence
summary and
practice
recommendation
was answer the
following
question: What
is the best
available
evidence
regarding
strategies to
reduce pain
associated with
intramuscular
injections?
Taddio, A., Shah, V.,
The purpose of
McMurtry, C. M.,
this systematic
MacDonald, N. E., Ipp, review was to
M., Riddell, R. P.,
evaluate a

Evidence
summary and
practice
recommendation

A RCT with 60
participants; a
RCT with 75
participants; a
RCT with 123
participants; a
quasiexperimental
study with 48
participants; a
systematic review
and network
meta-analysis
including 23
RCTs; a RCT
with 65
participants

Critical outcome
of consideration
was pain;
measurement
tools were
multimodal and
varied based on
study

There are several strategies that
have been used successfully to
reduce pain associated with IM
injections (air-lock technique, Ztrack technique, manual
pressure, topical anesthetics, and
Buzzy® device). Evidence does
not recommend one strategy over
the other; the use of clinical
judgment, taking patient
preference into account, is
recommended.

Level
IV
Grade
A

Systematic
Review

The sample
consisted of a
total of 31
studies; 24

Critical
outcomes
included pain,
distress, and

Interventions with a statistical
significance indicating pain
reduction included no aspiration,
injecting most painful vaccine

Level II
Grade
B
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Noel, M., &
Chambers, C. T.
(2015).

Yilmaz, G., &
Alemdar, D. K. (2019).

variety of
procedural and
physical
interventions on
pain levels
during
vaccination in a
variety of age
groups.

The purpose of
this study is to
compare the
efficacy of the
Buzzy® device,
ShotBlocker®,
and bubble
blowing in
reducing pain in
children.

Prospective RCT

studies included
children, 4
studies included
adults, and 3
studies included
adults and
children. The
number of
participants
totaled 11,880.

fear. A variety of
tools were used
to measure
these outcomes
based on age
and study.

The sample
consisted of 160
children ages 510 years. There
were four
subgroups with
40 randomized
participants in
each: Buzzy®
group,
ShotBlocker®
group, bubbleblowing group,
and control group
(no intervention).

The primary
outcome
measured in
this study was
pain with
secondary
outcome
measure of fear.
Instruments
used to
measure
included
interview forms,
procedural fear
(CFS), and pain
scores via
Oucher scale.

last, simultaneous injections,
vastus lateralis injection,
positioning interventions, nonnutritive sucking, external
vibrating device with cold
(Buzzy®), and muscle tension.
The results for Buzzy® use in
children ages 3-17 years were as
follows: SMD –1.23; 95% CI: 1.58, -0.87.
Mean scores for pain (selfreported (SD)) where p < 0.05:
ShotBlocker®: 4.14 (2.12)
Buzzy®: 3.87 (1.79)
Bubble-blowing: 4.75 (1.74)
Control group: 6.72 (2.16)
ShotBlocker®, Buzzy®, and
bubble-blowing all had significant
findings for reducing pain, with
Buzzy® having the most
significant results for pain
reduction.
Mean scores for fear according to
CFS (self-reported (SD)) where p
< 0.05:
ShotBlocker®: 1.66 (0.53)
Buzzy®: 1.35 (0.61)
Bubble-blowing: 1.88 (0.61)
Control group: 2.82 (0.66)
ShotBlocker®, Buzzy®, and
bubble-blowing were all effective

Level I
Grade
A
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in reducing fear, with Buzzy®
being the most effective.

Construction of Evidence-based Practice
Synthesis of Critically Appraised Literature
Therapeutic Techniques During IM Injections
The search for a method of pain relief during IM injections and other needle-based
procedures has proven to be an endeavor with widespread attempts and a variety of outcomes.
Based on the literature, therapeutic interventions and methods of pain relief regarding these
procedures include distraction techniques, manual pressure at the injection site, acupressure, Ztrack technique, the Buzzy® device, and the ShotBlocker® device (Öztürk et al., 2017; Şanlialp
Zeyrek et al., 2019; Stephenson, 2019). While many of the interventions revealed significant
efficacies, few of them have adequate bodies of evidence supporting their widespread, versatile
use in the clinical setting.
When looking at the body of literature and studies comparing interventions, there were
two main interventions with authentic bodies of evidence and supporting efficacy: the Buzzy®
device and the ShotBlocker® device (a plastic, horseshoe-shaped device used to apply manual
pressure at the injection site). After finding high level, high quality pieces of evidence comparing
these two interventions, it was clear the Buzzy® device was superior in efficacy in both the
pediatric and adult populations (Sivri Bilgen & Balcı, 2019; Yilmaz & Alemdar, 2019).
The Buzzy® device combines cryotherapeutic topical analgesia with tactile stimulation to
reduce pain at the injection site using principles of the Gate Control Theory illustrating
significant outcomes across a variety of populations – pediatric and adult alike (Ballard et al.,
2019; Bergomi et al., 2018; Canbulat et al., 2015; Şahin & Eşer, 2018; Taddio et al., 2015). The
device comes in a bee-shaped design, with ice pack wings for cooling and a main body that
vibrates; these work in combination to distract nerve fibers. The Gate Control Theory suggests
pain sensation is transmitted from the peripheral nervous system to the central nervous system,
where it is modulated by a gating system in the dorsal horn of the spinal cord and can reduce
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the pain information transmitted to the brain (Ballard et al., 2019; Bergomi et al., 2018; Canbulat
et al., 2015; Şahin & Eşer, 2018). Afferent pain-receptive nerves are blocked by fast nonnoxious motion nerves; the prolonged cold exposure (30 to 60 seconds), stimulates C fibers to
transmit a slow pain and noxious thermal information to the brain. Simultaneous to this reaction
in the nervous system, the Buzzy® device also uses distraction techniques, which can also
contribute to reducing fear and anxiety in those undergoing needle-based procedures (Ballard et
al., 2019; Bergomi et al., 2018; Canbulat et al., 2015; Şahin & Eşer, 2018).
Pain as Primary Outcome Measure
Vaccine injections are the most frequent painful medical procedure performed worldwide
(Taddio et al., 2015). Common factors affecting pain associated with IM injections include
anxiety, patient position, medication volume and viscosity, chemical composition of the drug,
solution of the drug, rate of delivery, injection technique, and location of the injection site (Öztürk
et al., 2017; Şahin & Eşer, 2018; Taddio et al., 2015). Among the various studies and pieces of
evidence appraised, the primary goal and outcome measured with needle-based procedures
was the same: the participant experiencing pain relief.
Different tools and methods were utilized to measure pain depending on population,
setting, and participant age group. For young pediatric populations, the Wong-Baker Faces
Scale was used (Ballard et al., 2019; Bergomi et al., 2018; Canbulat et al., 2015; Sivri Bilgen &
Balcı, 2019; Taddio et al., 2015). This scale consists of six animated faces that range from
neutral expression (0 = very happy/no pain) to a screaming face (10 = hurts more than you can
imagine) (Canbulat et al., 2015). One study utilized the Oucher pain scale for measurement of
pain scores. This scale is appropriate for use in children aged between 3 and 12 years and
comprises of two distinct scales. The first scale uses a series of six photographs of a child in
varied degrees of distress and is intended for children who cannot count. The second scale
uses the numbers 0 and 10 to indicate levels of distress distributed among the photographs to
identify pain level (Yilmaz & Alemdar, 2019). For adolescent and adult populations relevant for
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this project, the most commonly used pain measurement tool was the Visual Analog Scale
(Canbulat et al., 2015; Şahin & Eşer, 2018; Şanlialp Zeyrek et al., 2019; Sivri Bilgen & Balcı,
2019). This scale consists of a line 100 mm long; one end of the line reads “No pain” and the
other end of the line reads “Unbearable pain.” The participant is asked to mark the area on the
line that most accurately correlates with their experienced level of pain. To determine an
approximate pain level, a measurement is made from the “No pain” line to the participant’s
indicated mark in millimeters (Şahin & Eşer, 2018).
In many of the studies, self-reported pain was recorded with observed pain scores,
perceived fear levels, and perceived anxiety levels from parents or a nurse (Ballard et al., 2019;
Bergomi et al., 2018; Canbulat et al., 2015; Yilmaz & Alemdar, 2019). By incorporating patientstated pain scores with observer findings and secondary outcome measures, a more wellrounded approach at determining efficacy was employed for data analysis.
Age Group Specificity
Many of the studies performed look at pain reduction in children; regardless of age,
patients in general are often fearful of injections because they are perceived as a pain
producing procedure. It has been reported that 30.6% of patients – not just children – have
injection fear (Şahin & Eşer, 2018). The versatile use of cryotherapeutic topical analgesia
vibration is supported by the literature for effective means of reducing pain with needle-based
procedures for patients or all ages (Ballard et al., 2019; Bergomi et al., 2018; Canbulat et al.,
2015; Şahin & Eşer, 2018; Sivri Bilgen & Balcı, 2019; Taddio et al., 2015; Yilmaz & Alemdar,
2019). Much of the research found on the Buzzy® device involves pain reduction with needlebased procedures in children, but the described mechanism of action and effects of on the
nervous system via Gate Control Theory are transferable and applicable to adolescent and adult
populations undergoing the same types of procedures (Ballard et al., 2019; Bergomi et al.,
2018; Canbulat et al., 2015; Şahin & Eşer, 2018).
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Best Practice Model Recommendation
Reviewing the evidence determined best practice recommendations to reduce pain with
IM injections involves several strategies that show promise. The evidence demonstrates a lack
of definitive evidence to promote one strategy over the rest. Ultimately, a combination of clinical
judgment and patient preference should be utilized when endeavoring to reduce injection site
pain (Stephenson, 2019). Within the literature, there is significant support for best practice to
utilize the Buzzy® device to reduce injection site pain (specifically intramuscular injections as
immunizations) which applies across a variety of ages (Ballard et al., 2019; Bergomi et al.,
2018; Canbulat et al., 2015; Şahin & Eşer, 2018; Sivri Bilgen & Balcı, 2019; Taddio et al., 2015;
Yilmaz & Alemdar, 2019). By using a nonpharmacological intervention that works based on the
Gate Control Theory, pain can be diminished without the associated risks of using another
chemical substance and considering the practicality of time efficiency, accessibility of the
setting, usefulness in multiple age groups, and ability to reuse the device (Canbulat, Ayhan, &
Inal, 2015).
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CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
A change in practice was initiated to reduce the amount of discomfort, pain, and injection
fear associated with college-aged students receiving a vaccination. More literature has been
published in recent years with the primary goal of pain reduction and an additional emphasis
that healthcare professionals have an ethical obligation to diminish the level of pain their
patients experience, regardless of age or procedure (Bergomi et al., 2018; Öztürk et al., 2017).
Research shows that poor experience with needle-based procedures can lead to
noncompliance with vaccinations later in life and vaccination hesitancy from parents to their
children, bringing to light a significant public health issue (Ballard et al., 2019; McMurtry et al.,
2015). The EBP project initiating a noninvasive, nonpharmacological intervention that combines
more than one method of pain relief, both easy to use and economical, aids in vaccination
compliance and positively impacts public health.
Participants and Setting
The EBP project was performed in a health center at a university in northern Indiana.
There were a variety of key stakeholders that were essential to the efforts made toward
integration of a practice change. In this office setting, there was one part-time physician, one
full-time nurse practitioner, two part-time NPs, a full-time registered nurse, a full-time medical
assistant, a medical assistant, and a NP acting as director of the health center. Participation
from the registered nurse and medical assistant were essential as they are the primary
administrators of vaccinations and other IM injections at the health center. The intervention
selected for this project directly impacted the way they practice, so their participation and
compliance were significant factors. Patients considered eligible for this project included (a)
students enrolled at the university, (b) aged 23 and under, (c) students requiring a vaccination,
(d) who had not received the vaccination they were receiving before. Patients were excluded
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from participating if they (a) had extreme cold sensitivity, (b) nerve damage or sensory deficit

that would affect sensation where the injection took place, (c) had neurodevelopmental delays
or difficulties, (d) there was a lesion or break on the skin in the area the device would be placed
for pain relief during the injection procedure.
Pre-Intervention Group Characteristics
With the new virus COVID 19, the fall 2020 semester students to maintain enrollment at
the university were required to have multiple vaccinations. Some of these vaccinations require
an injection series including for example the meningitis-B (Men-B) vaccination. Freshman and
incoming students who met the inclusion criteria were the targeted group for this project due to
the need for vaccines, as many established students have previously received these
vaccinations as a requirement for previous university enrollment. Students were considered
eligible if receiving a vaccine series or if they were receiving more than one single-dose
vaccination. All students who met the inclusion criteria were considered viable candidates for
the project as long as there was a viable non-intervention vaccine to use as comparison with an
intervention-correlated vaccine.
Intervention
Prior to the start of implementation of the Buzzy® device component of the EBP project,
an in-service was completed to educate the medical assistant and registered nurse on staff. The
education was provided on how to use the Buzzy® device. An informative meeting took place
about the pain scale being utilized, how to use the device, and to review standardized preintervention and intervention protocols. Questions were addressed and staff was able to
practice with the device prior to using it on patients.
The intervention for this EBP project was selected based on a critical appraisal of a large
body of literature. The result was the development of a standardized protocol for preintervention IM injection and a standardized protocol for using the intervention. By having
standardized protocols, uniformity in administration between participants was more likely to be
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achieved and high-integrity data collected. The intervention selected for this project was the
Buzzy® device, which utilizes a combination of vibration (tactile stimulation) and cold
(cryotherapy) therapies. The device is bee-shaped with ice pack wings and is a battery-operated
motorized device that is reusable and easy to clean. The combination of vibration and prolonged
cold exposure has been proven to be an effective means of pain relief, and the Buzzy® device
has been shown to have statistically significant results in diminishing injection site pain in both
children and adults (Sahin & Eser, 2018; Canbulat, Ayhan, & Inal, 2015; Tadio et al., 2015).
The first process of the intervention started when students arrived at the health center.
When patients met the aforementioned inclusion and exclusion criteria they were asked to
participate. The student was then given the authorization and consent form. If a signature was
obtained, the participant proceeded to get their first injection of their required vaccine (Appendix
A). After the procedure, their pain was measured via a self-reported visual pain scale and a
questionnaire about previous experiences with vaccination and injections was completed. If
applicable, their second appointment to complete the vaccination series was scheduled.
The second part of the intervention included when the participant obtained their second
vaccination or injection in their vaccination series. For a number of participants this was
immediately following their non-intervention vaccination and was a different type of vaccination
on their other arm. For participants receiving a series, their second injection was received after
the allocated time (for example, the Bexsero Men-B series requires one month between
injections). Some participants compared the Buzzy® intervention with their vaccination to
previous vaccine experience, but that experience had to be within the previous year and if the
participant was confident they could accurately recall their previous experience. For all second
injections, the Buzzy® device was used for pain reduction. Upon patient arrival, ice pack wings
were removed from the freezer to allow thawing prior to the procedure. When the participant
was ready for the injection, the device was placed at the injection site for simultaneous vibration
from device and cooling from the ice pack wings. The device was left at the site for 30 seconds
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prior to injecting; during the course of the injection, it was placed just above the injection site so
that the analgesic effect could continue. Pain scores were reported immediately post-injection
through a questionnaire (Appendix B). For all participants, pain scores were measured using a
self-reported visual pain scale.
To promote uniformity within injection techniques as much as possible, standardized
non-intervention and intervention protocols were developed based on guidelines. These were
utilized so that during injections, elements such as needle length, needle gauge, injection site,
and injection technique would affect patient experience and pain scores as little as possible
(Appendices C and D).
Many students scheduled their vaccinations at the health center due to its proximity and
convenience to campus instead of having to drive to another health practice location.
Participants were recruited as they arrived for scheduled vaccinations. The participants had to
be able to read and write in English to sign the authorization and consent form that would allow
them to use the Buzzy® device for vaccine injection requirements for the university
Comparison
The first step in the intervention allowed for patients to be measured at baseline before
introducing the Buzzy® device to reduce pain with IM injections. The first injection each
participant received was completed with no intervention based on standard of care techniques
using a protocol distributed by the project manager. Immediately post-injection, pain scores
were reported and recorded. The second step in the intervention measured pain with the
participant’s second injection while using the Buzzy® device. Again, pain scores were reported
and recorded immediately post-injection. The comparison allowed for the end goal of decreased
pain sensation experienced while being injected using the Buzzy® device. By comparing two
injections under circumstances as similar to each other as possible aside from Buzzy® use, it
was determined that the most accurate data could be collected because participants’ pain
scores with and without the intervention would not be subject to variability in external factors.
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Outcomes
The primary outcome measured for this EBP project was pain. For this project, a visual
pain scale was utilized. The visual pain scale used for this project consists of a line that is 100
millimeters long. One end of the line reads “no pain.” In the middle of the line, it reads,
“moderate pain,” and the other end reads “unbearable pain.” This tool has been found to be a
reliable and valid means of measuring both acute and chronic pain in adults (Bijur et al., 2001).
Without a reliable and valid measurement tool, it is challenging to effectively manage pain of
any kind.
Participants scored their pain on the visual scale and their satisfaction immediately postinjection for both steps of the intervention, the intervention-free and Buzzy® intervention
injections. They were asked to make a point on the line that most closely correlated with their
pain level. The scores were collected by the nurse or medical assistant who performed the
vaccination. This information was then placed in a locked filing cabinet in the director’s office in
the health center where only the director and the project manager had access. The project
manager of the EBP project then measured the completed visual pain scales by the
participants. The score was obtained by measuring from the start of the “no pain” side to the
participant’s mark made on the pain scale line. This measurement was made to the millimeter
from zero to the participant’s mark.
The secondary outcome measured for this project was patient satisfaction. Directly
underneath the visual pain scale where participants recorded their pain for each encounter there
was a five-point Likert-type scale ranging from “Very Satisfied” to “Very Dissatisfied” where
participants could indicate how they felt about their non-intervention injection experience and
their Buzzy® injection experience. These were completed at the same time as the pain scores
by each participant.
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The questionnaire completed by participants obtained information on what vaccinations
they have received in the past, when they received their last vaccination, whether they receive
injections on a regular basis (including insulin injections, etc.), if needle-based procedures
produce fear or anxiety, and other demographic information (Appendix B). The final scores and
responses for both outcomes were recorded by the project manager. These along with the
paired questionnaires were obtained and placed in a locked file within a secure location
accessible to the project manager only.
Once data was collected, the primary and secondary outcomes were analyzed using a
paired t test, which was appropriate because two data measures were being taken on each
participant; there was no “experimental” and “control” group (Schmidt & Brown, 2019).
Time
The project lasted for the duration of the fall semester, beginning on August 24, 2020
until November 24, 2020, which was the end of the fall semester. This time frame was selected
for the project due to students returning to campus and requiring immunizations. Additionally,
many students utilized the health center for their vaccinations due to a variety of factors,
including convenience. Because of easy access, many students used the health center to
complete their vaccination requirements without having to leave campus and because of
continuity between the health center and the university.
Protection of Human Subjects
For the duration of this project, efforts were made to protect all human subjects from
excessive risk or harm of any kind. The project manager completed education for protection of
human subjects and an ethics course as part of DNP coursework in spring 2020. The CITI
program entitled “Social Behavioral Educational Research: Basic Course” was completed as
part of the requirements to initiate this project. Additionally, the project manager completed an
Institutional Review Board (IRB) questionnaire in July of 2020 to determine the level of approval
required by the university. Once it was determined that this project did not meet the federal
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criteria of research and that the study design and intervention would not lower the standard of
care or put participants at risk, IRB exemption was granted.
Prior to integration of the Buzzy® device into practice, participants were educated on
how the device works and what participation included through the authorization and consent
form. Questions were answered to the participants’ satisfaction and the authorization and
consent form was signed. Participant confidentiality and voluntary participation were
emphasized and confirmed. Participants were able to cease participation in the project at any
time should they wish. The questionnaire and both pain scales were obtained and placed in a
locked filing cabinet within a secure location accessible to the project manager only.
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CHAPTER 4
FINDINGS
The purpose of this EBP project was to determine the efficacy of cryotherapy and
vibration via Buzzy® device in reducing injection site pain with vaccinations in young adults. The
desired primary outcome was reduced self-reported pain measured using a visual pain scale.
Individuals who consented to participate first completed a questionnaire which included
demographic characteristics and background information about previous experience with
injections. The first pain measurement was reported pre-intervention when the participant
received a vaccination. The second self-reported pain measurement was taken by the same
participant after receiving a vaccination with the Buzzy® device. After completion of the
questionnaire noted in the previous chapter’s full description of the project intervention, analysis
was completed for all variables to determine if there were pertinent and relevant outcome
findings.
Participants
Size
Throughout the course of implementation, a total of 38 participants meeting the project
implementation criteria were recruited and consented to participate. Each participant recorded
pre-intervention vaccination pain scores as well as post-intervention pain scores after receiving
a vaccination with the Buzzy® device.
Demographics
Demographic characteristics were collected for the sample using the questionnaire each
participant completed when they consented to participate. The questionnaire was formatted to
gathering information on the student identification number, student email, ethnicity, gender, and
age. Other information on the questionnaire, descriptive information, gathered from the
participants were recent vaccination, completed vaccinations, regular injection status, anxiety

42

DON’T BE SUCH A BUZZY®KILL
frequency and associated sources with injections. There was a total of 10 males and 28

females, and ages of participants ranged from 18 to 23 years, with ages 18 and 19 being most
common and accounting for 55% of the sample. The injection types for the pre-intervention and
intervention groups varied between participants and non-intervention and intervention groups.
The race/ethnicities within the sample included the following: 26 white, four of two or more
races, three not listed, two Asian, one black, one Hispanic/Latino, and one international student.
The descriptive statistics on the questionnaire contained specific questions that
pertained to how the participants felt about needle injections. When asked if injections cause
fear or anxiety, 21.1% of the participants said always and 23.7% of the participants said
sometimes. However, 28.8% of the participants said injections never cause them fear or anxiety
and 21.1% of the participants said it rarely did. The next question in the questionnaire looked at
the cause of the anxiety or fear. 44.7% of the participant’s source of anxiety was pain of the
injection and 21.1% had a previous bad experience. The full data of the descriptive statistics
from the questionnaire of the sample group are detailed in Tables 4.1 and 4.2.
Changes in Outcomes
This EBP project addressed the following PICOT question: In college-aged students
receiving immunizations (P), does the Buzzy® device (I) when compared to non-intervention
standard of care (C) effectively reduce injection site pain (O) over a 12-week time period (T)?
The primary outcome measure was pain, and this was self-reported using a visual pain scale.
Statistical Testing and Significance
Data were entered into the SPSS version 25 for statistical analysis. The text, How to use
SPSS: A step-by-step guide to analysis and interpretation by Cronk (2019) was utilized to guide
the process of data input, analysis, and interpretation of data. Variation existed between the
types of non-intervention and intervention vaccinations between groups and individual
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Table 4.1
Demographic Characteristics
Demographic
Number of participants
Age
18
19
20
21
22
23
24
25
Gender
Male
Female
Race
Black
Two or More Races
Asian
Hispanic or Latino
International Student
White
Not Listed

Frequency (%)
38 (100%)
10 (26.3%)
11 (28.9%)
6 (15.8%)
1 (2.6)
5 (13.2%)
4 (10.5%)
0 (0.0%)
1 (2.6%)
10 (26.3%)
28 (73.7%)
1 (2.6%)
4 (10.5%)
2 (5.3%)
1 (2.6%)
1 (2.6%)
26 (68.4%)
3 (7.9%)
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Table 4.2
Descriptive Characteristics
Descriptive
Recent Vaccination
Yes
No
Vaccinations Complete at Initial Visit
Varicella
Hepatitis A
Hepatitis B
Measles, Mumps, Rubella (MMR)
Tetanus (DTaP, Tdap)
Meningococcal B (Men-B)
Meningococcal quadrivalent

Frequency (%)
26 (68.4%%)
12 (32.6%)
38 (100%)
38 (100%)
38 (100%)
38 (100%)
38 (100%)
15 (39.5%)
36 (94.7%)

Receive Regular Injections
Yes
No

2 (5.3%)
36 (94.7%)

Non-Intervention Injection Type
Bexsero (Men-B)
Trumenba (Men-B)
HPV
Influenza
Immunotherapy/Allergy
Tetanus

21 (55.3%)
2 (5.3%)
3 (7.9%)
9 (23.7%)
1 (2.6%)
2 (5.3%)

Buzzy® Injection Type
Bexsero (Men-B)
Trumenba (Men-B)
HPV
Influenza
Immunotherapy/Allergy
Tetanus

21 (55.3%)
1 (2.6%)
2 (5.3%)
13 (34.2%)
1 (2.6%)
0 (0.0%)
3 (7.9%)

Anxiety with Injections
Always
Sometimes
Neutral
Rarely
Never

8 (21.1%)
9 (23.7%)
2 (5.3%)
8 (21.1%)
11 (28.9%)

Source of Anxiety with Injections
Pain from Injection
Previous Bad Experience
Other
Not Applicable

17 (44.7%)
8 (21.1%)
2 (5.3%)
11 (28.9%)
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participants. When variation exists, the statistical test used is a one-way ANOVA, which was
applied to the data analysis between the non-intervention pain scores and non-intervention
injection type. The same statistical test was performed for the Buzzy® intervention pain scores
and injection types. This was completed to determine if there was statistical significance
associated between pain score and injection type. In analysis of non-intervention injection types
and pain scores, the overall significance of the one-way ANOVA was 0.092 where p < 0.05,
showing there is not sufficient evidence to indicate a significant relationship between pain score
and injection type in the non-intervention data set. For the one-way ANOVA performed on the
Buzzy® intervention injection type and associated pain scores, the significance was 0.170
where p < 0.05, also showing there is not sufficient evidence to indicate a significant relationship
between injection type and pain score.
In addition to this, a Chi-square was performed between non-intervention injection type
and Buzzy® intervention injection type to determine if there was a statistical significance
between the varied injection types in both groups. The Pearson Chi-square value was 8.173 df
= 20; sig. = 0.004 where p < 0.05. This indicated a statistically significant difference in variation
of injection type between the non-intervention and Buzzy® data sets.
Primary outcome. The primary outcome measure for this project was pain with the use
of the Buzzy® device for the injection, measured with a visual pain scale. This scale consisted
of a line 100 millimeters long. One end of the line read “no pain.” In the middle of the line, it
read, “moderate pain,” and the other end read “unbearable pain.” Participants indicated their
pain on the scale immediately after their injection was completed. A paired samples t test was
conducted to compare non-intervention pain scores and Buzzy® pain scores. Findings showed
that t = 8.674, df = 37, and a mean decrease in pain of 2.32 (SD = 1.65) where p <0.05. The
mean non-intervention injection pain score was 4.71 (SD = 1.86) and the mean Buzzy®
injection pain score was 2.39 (SD = 1.51). These findings indicated a statistically significant
relationship in improvement with pain scores for IM injections when using the Buzzy® device.
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Secondary outcome. The secondary outcome measure for this project was participant
satisfaction with the use of the Buzzy® device for the injection. This was measured via a fivepoint Likert-type scale with options Very Satisfied, Satisfied, Neutral, Dissatisfied, and Very
Dissatisfied where participants could indicate how they felt about their non-intervention injection
experience and their Buzzy® injection experience. These were completed at the same time as
the pain scores by each participant. A paired samples t test was used to compare mean scores
between the two groups. When performing data analysis, the number 1 indicated Very Satisfied
and the number 5 indicated Very Dissatisfied, the mean non-intervention satisfaction score was
2.45 (SD = 1.11) and the mean satisfaction with the Buzzy® was 1.55 (SD = 0.69) where p <
0.05. The results showed t = 4.969, df = 37, and a mean difference between the two groups of
0.90 (SD = 1.11). This indicates there was a statistically significant relationship in improvement
with satisfaction with use of the Buzzy® device for IM injections.
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CHAPTER 5
DISCUSSION
This EBP project was conducted with the purpose of answering the PICOT question, "In
college-aged students (P), does the Buzzy® device (I) when compared to non-intervention
standard of care (C) effectively reduce injection site pain (O) over a 12-week time period (T)?” A
protocol was developed and utilized to determine the efficacy of vibration and cryotherapy via
the Buzzy® device in reducing self-reported pain with immunizations. This chapter will expound
upon project findings and statistical analysis, as well as consider the application of the EBP
model used to guide this project. Strengths and limitations of the project will be discussed along
with implications for future research, practice, theory, and education.
Explanation of Findings
Project findings supported the effectiveness of using the Buzzy® to deliver a
combination of vibration and cryotherapy to reduce pain levels during vaccinations in collegeage students. Additionally, project findings showed a statistical significance in affecting the level
of satisfaction participants had with their experience getting their vaccination. Participant
findings including sample size and demographic characteristics will be further discussed later in
the chapter.
Participant Findings
Based on information from the current body of literature, there was variation in sample
sizes used in RCTs and in the RCTs used for systematic review. Most sample sizes ranged
from 120-170 participants, so the sample size for this project with 38 participants is relatively
small. The project did not take place in a large health corporation or large office setting, so it is
logical that the sample size would be lesser than in the evidence used in the literature review.
Additionally, this project was conducted in a small age range because it looked at college-aged
students ages 18-25. Another large contributing factor was the project took place during the
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COVID-19 pandemic. This pandemic limited students to online learning and ability to be present
on campus to visit the health center. Not only was the COVID-19 pandemic a factor, the project
took place in the fall of 2020 during the height of the pandemic when numbers were the highest
in the state of Indiana in making recruitment of participants more difficult. All of these factors
likely contributed to having a smaller sample size.
The sample for this project comprised of 73.7% female and 26.3% male participation.
Evidence included in the literature review had a variety of gender-related proportions. For
example, Yilmaz and Alemdar (2019) also had higher levels of female participation with a
narrower differential with 52.5% being female and 47.5% being male. Öztürk et al. (2017) had
higher female participation at 87.3% female and 12.6% male in the experimental group and
91.7% female and 8.3% male in the comparison group. Additionally, Şahin and Eşer (2018) had
participation of 60.6% female and 39.4% male in the application group and 68.8% female and
31.3% male in the control group. The higher proportions in the research studies that females
were more likely to participate than males were consistent with those in this EBP project.
In terms of demographic data that considered race and ethnicity, none of the reviewed
evidence included this information. In this project, 68.4% of participants reported that their
ethnicity was white or Caucasian, which is a substantial amount. However, this proportion is
consistent with the population in the area and enrolled at the university. At the university in
northern Indiana where his EBP project was conducted, 70.6% of students are Caucasian
(Enrollment by Race/Ethnicity, 2020), so this was an anticipated finding.
Pain Results
Statistically significant results were found between the non-intervention and Buzzy®
intervention groups in terms of self-reported pain on the visual pain scale. The reported pain
scores indicated that there was a notable decrease in pain when participants received an
injection with the Buzzy® device rather than without an intervention. The mean non-intervention
injection pain score was 4.71 (SD = 1.86) and the mean Buzzy® injection pain score was 2.39
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(SD = 1.51). The results of this outcome measure were consistent with the results found in the
literature review that concluded the Buzzy® was an effective means of pain reduction with IM
injections (Ballard et al., 2019; Bergomi et al., 2018; Canbulat et al., 2015; Şahin & Eşer, 2018;
Sivri Bilgen & Balcı, 2019; Taddio et al., 2015; Yilmaz & Alemdar, 2019). Therefore, it can be
determined that these results had sufficient evidence to support the benefit of using the Buzzy®
device for pain reduction in college-aged students.
It is also important to discuss the other statistical tests performed. Because there were
differences between the type of injections in the non-intervention data set and the Buzzy®
device data set, a one-way ANOVA was performed between the non-intervention pain scores
and non-intervention injection type, as well as the Buzzy® intervention pain scores and injection
types. This was performed in order to detect whether there was statistical significance
associated between pain score and injection type for both data sets. For non-intervention
injection types and pain scores, it was determined that there was not sufficient evidence to
indicate a significant relationship between pain score and injection type in the non-intervention
data set. For the one-way ANOVA performed on Buzzy® intervention injection type and
associated pain scores, the significance also indicated there was not sufficient evidence to
indicate a significant relationship between injection type and pain score. These findings
reinforced that injection type for both data sets was not an indicator of pain and did not influence
individual self-reported pain scores.
In addition to this, a Chi-square was performed between non-intervention injection type
and Buzzy® intervention injection type to determine if there were significant differences between
injection type and frequency given in both data sets. The Pearson Chi-square value (8.173, df =
20; sig. = 0.004 where p < 0.05) indicated a statistically significant difference in variation of
injection type and frequency between the non-intervention and Buzzy® data sets. The most
likely source of this was that there were nine participants who had the influenza vaccination as
their non-intervention injection and there were 13 who had their influenza vaccination as their
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Buzzy® injection. While this was noted, it was not listed as a limitation because other statistical
tests determined that there was not a significant relationship between injection type and pain
score.
Patient Satisfaction
Patient satisfaction was the secondary outcome measure for this project and was
measured on a five-point Likert-type scale. The mean non-intervention satisfaction score was
2.45 and the mean satisfaction with the Buzzy® was 1.55. The mean difference between the
two groups was 0.90 The non-intervention value fell between “Satisfied” and “Neutral” on the
scale and the value obtained after use of the Buzzy® fell between “Very Satisfied” and
“Satisfied.” The values obtained indicate that there was a statistically significant relationship
between non-intervention satisfaction and satisfaction with the Buzzy® device. This evidence
supports that participants were more satisfied with their experience while using the Buzzy®
device than without the device, which is logically congruent with the overall statistically
significant decrease in pain.
Strengths and Limitations of the DNP Project
There were a variety of strengths and weaknesses that arose throughout project
implementation that can be explicated and utilized to guide future projects related to this topic.
EBP Model
The JHNEBPM was utilized as a framework to guide the development, implementation,
and evaluation of this project. By providing a comprehensive yet flexible outline, this EBP model
was useful in creating a stepwise progression that the project manager could use to evaluate
progress and adjust the execution of this project as necessary to for successful implementation.
Strengths. The JHNEBPM was a good fit for this project for several reasons. The model is
relatively easy to understand, helping to guide a novice project manager in project planning,
implementation, practice change, project evaluation, and data analysis. Because of this, the
detailed steps outlined by the model were integral in guiding the consideration of aspects that
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may have been overlooked or disregarded. There are three phases in the JHNEBPM: practice
questions, evidence, and translation. Within these three phases are 19 steps that were closely
followed through the implementation of this EBP project (Dang & Dearholt, 2017; Melnyk &
Fineout-Overholt, 2019). The practice question phase laid the foundation of this project by
identifying a practice problem that was important for implementation in practice. This was
brought to the project manager’s attention by way of the staff at the university health center. A
self-reported history of discomfort and anxiety with IM injections and vaccinations created a
passionate idea identifying a viable intervention addressing this issue. After doing a thorough
review of the literature and considering possible interventions, the strongest and largest amount
of evidence pointed toward the Buzzy® device. This practice change was suggested and a plan
for the project and implementing practice change was developed. Through the evidence phase
of the model, evidence was collected and appraised. After this was complete, a summary and
synthesis of the evidence was completed to aid in the direction of recommendations for practice
change. The project manager, site facilitator, and staff together determined whether the practice
change was realistic, manageable, and appropriate for their patients and setting. After
discussing a plan of action with the site facilitator and staff, the university generously purchased
the Buzzy® devices for the project. During implementation, modifications were made to include
multiple injection types, but the premise remained the same. The project manager was able to
gain access to the electronic medical record and do the majority of injections to promote
continuity throughout the project as well, which helped with adopting the translation process.
Results of the project were collected by the project manager and evaluated through SPSS for
statistical significance. Findings were reported to key stakeholders and methods of
dissemination were identified and discussed. Since then, the project site has continued use of
the Buzzy® for vaccinations, immunotherapy injections, and other needle-based procedures
performed at the clinic. Without the use of the JNHEBPM to develop, implement, and evaluate
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this EBP project, the continued use of the Buzzy® device at the health center for injections and
needle based procedures would not be presently in use helping college age students every day.
Strengths of the Project
There were a number of strengths of this project that became evident throughout the
course of implementation and evaluation. One of the largest strengths were the amount of
support from the site facilitator and other staff on site. They were enthusiastic about the project,
asked questions, and willingly used the Buzzy® device to participate in data collection. The staff
when educated on the EBP project and use of the Buzzy® device, did not show opposition to
change and supported the positive evidence provided about the Buzzy® device. Their
willingness to adjust the standard of care typically given for vaccinations played a significant
part in contributing to project success as many times one of the major setbacks in
implementation is reluctance to change. Additionally, participants that were recruited as they
arrived for vaccinations and met the inclusion criteria were generally eager and willing to
participate, which made the project possible.
One of the most important strengths of this project was its simplicity in many aspects
from the intervention, to the education given to staff, and to the questionnaires given to the
participants. The EBP was straightforward and easy to understand, which tied together many of
its success including the strengths noted above, staff participation and individuals agreeing to
participate. The questionnaire was limited in questions for the participants to complete and there
were minimal places where they had to write information. With this formatted questionnaire, it
was less daunting for students when filling out, was simple, and could be completed in a timely
manner. When the staff used the Buzzy® device, it did not add time to the overall completion of
injections so it was easy to incorporate without sacrificing time or staying on schedule, which
were important factors in integrating the device into practice. The two outcome measurements
that were self-reported and independent of the facility’s charting system were helpful in not
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adding time to documentation for the staff and allowed participants to be engaged in data
collection.
To minimize the effects of external factors, standardized non-intervention and
intervention protocols were derived from guidelines in order to rule out factors such as needle
gauge, needle length, variation in injection site, different techniques between injection
administrator, etc. Handouts in the form of a 21 step standardized injection protocol nonintervention and a 23 step standardized injection protocol Buzzy® device were provided to the
staff after education for during the intervention. By educating staff, providing these simple stepby-step handouts, and promoting communication between project manager, staff, and site
facilitator, adjustments were made efficiently, the project stayed on track, the injections
continued to be given properly with the device, and goals of this project were accomplished.
Limitations of the Project
While there were a number of strengths associated with this project, there were also
several limitations that should be addressed. First, modifications were made to accommodate
the potential of the university health center closing. Unfortunately, this project took place during
a pandemic, COVID-19, which created uncertainty throughout the United States and for this
project. Because of the threat of COVID-19 and the possibility of campus closure, the first
adjustment made was to include several injection types. Another major adjustment was the
varying time periods between first and second injections between individual participants so that
sufficient data could be collected before the would-be closure occurred.
Initially prior to the COVID-19 accommodations that needed to occur due to the
unknowns, the plan for the EBP project was utilizing the Men-B vaccination series as it was the
same vaccine injection and time period and is required for school enrollment. Because of
COVID-19, the EBP project changes had differences in injection types between data sets and
for individual patients. Even though protocols were implemented to promote continuity in factors
such as needle size and length, having different vaccinations that could vary in serum viscosity

DON’T BE SUCH A BUZZY®KILL

54

and have the potential to influence pain levels was not ideal. To make sure this was accounted
for, data analysis was performed, which did not show significant relationships between
individual injection types and reported pain. In the future given the small sample size of this EBP
project, this could be looked into further with a larger sample size to see if there was statistically
significance between using different vaccinations among the participants.
Other limitations present in the EBP would be the sample size and demographics
including BMI. With a larger sample size more data could be collected that could change the
statistical significance of the EBP project primary and secondary outcomes. The EBP sample
size of 38 participants provided sufficient evidence but having a larger pool of data to analyze
could provide more accurate outcomes. Also, certain demographics that have the potential to
affect pain, such as body mass index (BMI) was not collected as part of data for this project. It
has been determined that thin patients can report less pain than their normal-weight or obese
counterparts (Şahin & Eşer, 2018). As noted in a strength of the project, keeping to a simplistic
project to not only gain support of the site in which it was implemented at, but having willingness
of participants wanting to be a part of the study was needed especially with the limitations due
to COVID-19 unknowns. For this reason the question of BMI was left out of the questionnaire
during data collection. This information was not collected but could have been an indicator of
perceived pain that affected patient outcomes.
Implications for the Future
This EBP project provided valuable information for both the advanced practice nursing
population and the global healthcare community by exploring pain relief during vaccination.
Future implications for practice, research, theory, and education will be discussed, as well as
recommendations to improve future EBP projects and practice changes.
Practice
Using a combination of prolonged cold exposure and vibration via the Buzzy® device
has been supported as a best practice option for reducing pain with vaccinations by current and
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high-quality literature. This project served as a means to make this the standard of practice for
these procedures at the clinical site the project took place. The clinical site supported the project
and the cost of the Buzzy® devices was covered by the university. Since conclusion of the
project, the project site has continued use of the Buzzy® device in practice.
To aid with future EBP projects and integration into practice, a number of considerations
should be addressed. Even though sufficient evidence was collected, more accurate outcomes
could be obtained from having a larger sample with more ethnic, age-related, and genderrelated diversity. Additionally, promoting continuity of injection type or determining variability of
pain experienced between injection types would be helpful in determining true efficacy of the
device.
Research
Further research on other non-pharmacological interventions would aid in determining
the efficacy of the Buzzy® in the endeavor of truly establishing best practice. One of the other
interventions presented in the literature was the ShotBlocker®. There was not sufficient
evidence to support its use in lieu of the Buzzy® device but more research on this device could
present helpful information. Additionally, it would be helpful to look more closely at anxiety
associated with needle-based procedures and how closely it correlates with pain. Many
perceptions of pain from IM injections can come from anxiety as noted in the literature. Common
factors that affect pain associated with IM injections include anxiety, previous poor experiences,
patient position, medication volume and viscosity, chemical composition of the drug, available
solution of the drug, rate of delivery, injection technique, and anatomic location of the injection
site (Sahin & Eser, 2018). Data from this project showed that 65.8% of participants reported
anxiety due to injection pain or previous bad experience; this is a significant contributor to
patient experience and pain perception and should be considered for future research. Moreover,
it would be helpful to look into the pain caused by serum viscosity that could differ between
injection types and pain associated with different injection sites. This project performed IM
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injections in the deltoid muscle, but there are several sites that could have been utilized and this
may affect the amount of pain an individual experiences during an injection. Lastly, as
previously mentioned, there has been evidence that explores the difference in pain sensation
with distinctions in BMI. It is possible that patients with lower body fat percentage or composition
experience more pain than their counterparts with higher fat percentage that fall into normal and
obese categories; this should also be considered in the future.
Theory
The JHNEBPM was instrumental in the successful implementation of this project and in
integrating the Buzzy® device into practice. By detailing 19 steps, it ensured that this project
was implemented to its fullest extent without overlooking important aspects of changing
practice. The versatility of this model makes it an excellent candidate for other future EBP
projects because its concepts can be applied in a myriad of settings. For a more experienced
project manager, the rigor of 19 steps and three phases may not be necessary to successfully
implement EBP, so this should also be considered before selecting this model for an EBP
project.
Education
Education is an essential part of patient care and successfully implementing practice
change. Participants in this project were thoroughly educated prior to participating in this project.
This included information such as practice treatment, possible reactions to vaccinations, how
the Buzzy® device works, and the details of the project included in the authorization and
consent form that was signed prior to participation. Prior to project implementation, staff were
educated on protocols for non-intervention and Buzzy® injections, and a copy of these were
also kept in the immunization room for reference if needed. Additionally, a pamphlet on how to
use the Buzzy® that was included with the device from the company for staff reference. The
combination of these things allowed participants and staff to enter into this project fully informed
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about the changes to practice, and any questions that arose were answered by the project
manager.
Conclusion
The implementation of this EBP project allowed the project manager, site facilitator,
project site staff, and participants to see firsthand the value of using prolonged cold exposure
and vibration by means of the Buzzy® device to reduce pain during the administration of
vaccines. The site facilitator and staff have expressed their satisfaction with the device and
project outcomes, as well as their intent for continued future use. Participants verbalized their

approval of the device and hopes to use it in the future for their vaccinations. To conclude, the
results of this project provided sufficient evidence to support the use of the Buzzy® device to
reduce pain and increase satisfaction during vaccinations in college-age students. These
findings are consistent with the existing body of literature. Continued use of the device in
practice is encouraged for best-practice purposes. It is recommended to providers and staff to
incorporate prolonged cold exposure and vibration to reduce pain with vaccinations in an
efficient and affordable way by means of the Buzzy® device.
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ACRONYM LIST
BMI: Body Mass Index
CDC: Centers for Disease Control
CFS: Children’s Fear Scale
DNP: Doctor of Nursing Practice
EBP: Evidence-Based Practice
FPS-R: Faces Pain Scale-Revised
IRB: Institutional Review Board
IM: Intra muscular
IV: Intravenous
JBI: Joanna Briggs Institute
JHH: John Hopkins Hospital
JHNEBP: Johns Hopkins Nursing Evidence-Based Practice
JHNEBPM: Johns Hopkins Nursing Evidence-Based Practice Model
Men-B: Meningitis-B
NP: Nurse Practitioner
NRS: Numeric Rating Scale
PET: PET process
RCT: Randomized Controlled Trial
SPSS: Statistical Package For the Social Sciences
STAIC: State-trait Anxiety Inventory for Children
VAS: Visual Analog Scale
VRS: Verbal Rating Scale
WBFC: Wong Backer Faces Scale
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APPENDIX A

Authorization & Consent for Use of Buzzy® Device
Patient Name: ________________________ Birthdate: _______________________
Student ID#: _________________________
Project Title: Don’t be Such a Buzzy®kill: Using Cryotherapy and Vibration to Reduce Pain
During Vaccinations in College-Age Students.
Project Manager: Katy Long, BSN, RN, DNP Student Valparaiso University College of
Nursing and Health Professions
Purpose: This is a consent form for participation in an evidence-based practice project. Should
you decide to participate, it will provide important information about the project and tell you
what to expect as a participant. You are being asked to join an evidence-based practice project
for individuals receiving a vaccination that will assess the ability of the Buzzy® device to reduce
pain during the procedure.
Voluntary Participation/Withdrawal: Participation in this project is voluntary. Please read and
consider the information carefully. You may ask questions before making any decision regarding
participation at any time during or after the implementation of this project. You are free to stop
participating at any time without penalty, and your future visits at the health center will not be
impacted.
Procedure: Should you participate in this project, you are consenting to use the Buzzy® device
to decrease pain during vaccination. Prior to injection, the icepack portion of the Buzzy® device
will be removed from the freezer to thaw before placing directly onto the skin. The Buzzy®
device will then be placed at injection site for 30 seconds prior to the injection, allowing the area
to be slightly numbed before injecting. During the procedure, the Buzzy® device will be placed
slightly above the injection site. Both the icepack and vibration aspects will be operating and
may provide additional distraction from the procedure. Immediately following the procedure,
you will report your level of pain on a Visual Analog Scale (VAS), displayed as a line ranging
from “no pain” to, “worst pain.”
Duration: If you decide to participate in this project, the duration is from your attendance at an
initial focus group until your scheduled appointment to receive your vaccination. This is the only
time that contact with the patient will occur, with no necessary follow-up.
Risk: The risks associated with participating in this project are minimal. They may include the
side effects of skin contact with the cold temperature of an icepack or concerns regarding
discomfort associated with the vibration mechanism of the Buzzy® device.
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Benefits: The benefits of participating in this project include the utilization of evidence-based
care that works to reduce pain associated with intramuscular injection and improve patient
experience.
Confidentiality: The personal information and answers given on the questionnaire may be
reported and utilized by the project manager, but any information that can be used to personally
identify you as the participant will remain strictly confidential. Personal information will be
coded to maintain your confidentiality, and documents will be stored in a secured location
available only to the project manager.
Contacts and Questions: For questions and concerns about the project, the project manager,
Katy Long, can be reached at (219) 869-3144 or katy.long@valpo.edu. You may also contact the
health center with questions at (219) 464-5060. Heather Stricker, the faculty advisor for this
project, may be contacted at heather.strickler@valpo.edu.
Consent to Participate: You have read this form and are aware that you are being asked to
participate in an evidence-based practice project. You understand the information that has been
given to you and have had the opportunity to ask questions and have had them answered to your
satisfaction. By signing and submitting this form, you are agreeing to participate in this project.
A copy of this form will be offered for your records.
___________________________________
Participant Signature

__________________
Date

___________________________________
Guardian Signature (if applicable)

__________________
Date

Contact Information:
Student Name ____________________

Cell Phone Number _________________________

Student ID # _____________________

Student Email ______________________________

Can we contact you via text message?

Yes

No

Demographic Information:
Race/Ethnicity (Circle):
American Indian
Black
Native Hawaiian/Other Pacific Islander
Two or more races
Prefer not to say
Gender (Circle):
Age: ________

Male

Female

Asian
Hispanic or Latino
Non-resident alien (international student)
White
Not listed
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APPENDIX B
Questionnaire:
1. Have you recently gotten a vaccination?
Yes

No

2. If yes, what was your last vaccine? __________________________
3. When did you receive that vaccination? ________________________
4. Which vaccinations have you completed? Check all that apply.
Varicella (Chicken Pox)
Hepatitis A
Hepatitis B
Measles, Mumps, Rubella (MMR)
Tetanus (DTaP, Tdap)
Meningococcal B (MenB)
Meningitis/Meningococcal quadrivalent
Have you completed the first step in your Meningococcal B series, but not the entire
series yet? (Circle)
Yes
No
I have gotten both
5. Do you get injections on a regular basis of any kind (blood draws, insulin, allergy shots,
chemotherapy, etc.)?
Yes
No
If yes, what kind of injections do you receive? _________________________
6. Do needle-based procedures (such as an injection or shot) give you fear or anxiety in any
capacity?
Always

Sometimes

Neutral

Rarely

Never

7. If answered yes to the above question, what do you believe from the answers below
causes you the most anxiety about having a needle-based procedure?
a) The pain of the actual injection
b) Postinjection soreness at the injection site
c) Burning at the injection site
d) Previous bad experience with injection
e) Other
8. Would you like to make an appointment at the health center for your next vaccination or
next step in the sequence of your vaccination series?
Yes

No
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9. If yes, would you like to sign up for a text message reminder?

Yes

No

Rate the pain of your last (most recent) injection:

Injection type/name:__________________________

Date: ________________

How satisfied were you with the comfort level of your last (most recent) injection?
Very Satisfied

Satisfied

Neutral

Dissatisfied

Very Dissatisfied

Rate the pain of your injection while using the Buzzy® device:

Injection type/name: ____________________________

Date:________________

How satisfied were you with the comfort level of your injection with the Buzzy® device?
Very Satisfied

Satisfied

Neutral

Dissatisfied

Very Dissatisfied
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APPENDIX C
Standardized Injection Protocol: Non-Intervention
1. Gather equipment (gloves, alcohol prep, injection supplies, etc.)
2. Confirm patient identity and explain the procedure
3. Check the injection order in the patient’s chart, particularly: drug, dose, date and time of
administration, route and method of administration, diluent as appropriate, validity of
prescription, signature of provider.
4. Perform hand hygiene and put on clean gloves as required
5. Ensure patient privacy
6. Select appropriate administration site (for purposes of EBP project, typically deltoid site)
and identify appropriate landmarks
7. Determine appropriate needle length based on medication volume, body mass, and
depth of injection site
8. When using an ampule/vial to load the syringe prior to intramuscular (IM) injection, avoid
drawing up any air bubbles into the syringe. Change the needle prior to performing the
IM injection to ensure the needle is sharp and free from medication residue/particulates.
9. Remove the appropriate garments to expose the injection site.
10. Assist the patient into position to facilitate the injection into the chosen site, and
encourage patient to relax the target muscle.
11. If required, cleanse site with an alcohol swab for 30 seconds. Allow area to dry for 30
seconds.
12. Perform the injection using the Z-track technique. Using the index finger and thumb of
non-dominant hand, stretch the skin around the injection site so it is tight.
13. Holding the syringe like a dart in the dominant hand, inform the patient and quickly
plunge the needle at an angle of 90° into the skin. Aspiration is generally not required
unless injecting the vascular dorsogluteal site.
14. Depress the plunger at approximately one ml every 10 seconds, and slowly inject the
drug.
15. While withdrawing the needle, release the retracted skin at the same time to seal off the
puncture track.
16. Apply gentle pressure at the injection site, and then apply a small plaster over the
puncture site.
17. Do not recap needle. Discard all sharps into sharps container.
18. Remove gloves and dispose correctly according to local policy, along with other nonsharps.
19. Perform hand hygiene.
20. Chart and sign medication record appropriately.
21. Evaluate for any adverse response to medication.

Derived from:
The Joanna Briggs Institute. Recommended Practice. Injection: Intramuscular. The Joanna Briggs Institute EBP Database,
JBI@Ovid.2019; JBI2138.
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APPENDIX D
Standardized Injection Protocol for Buzzy®
1. Gather equipment (gloves, alcohol prep, injection supplies, etc.)
2. Confirm patient identity and explain the procedure
3. Check the injection order in the patient’s chart, particularly: drug, dose, date and time of
administration, route and method of administration, diluent as appropriate, validity of
prescription, signature of provider.
4. Perform hand hygiene and put on clean gloves as required
5. Ensure patient privacy
6. Select appropriate administration site (for purposes of EBP project, typically deltoid site)
and identify appropriate landmarks
7. Determine appropriate needle length based on medication volume, body mass, and
depth of injection site
8. When using an ampule/vial to load the syringe prior to intramuscular (IM) injection, avoid
drawing up any air bubbles into the syringe. Change the needle prior to performing the
IM injection to ensure the needle is sharp and free from medication residue/particulates.
9. Remove the appropriate garments to expose the injection site.
10. Assist the patient into position to facilitate the injection into the chosen site and
encourage patient to relax the target muscle.
11. Remove Buzzy® wings from freezer and attach to body of Buzzy® device. Instruct
patient to hold vibrating Buzzy® device over injection site for 60 seconds. After 60
seconds, have the patient move the device above the injection site.
12. If required, cleanse site with an alcohol swab for 30 seconds. Allow area to dry for 30
seconds.
13. Perform the injection using the Z-track technique. Using the index finger and thumb of
non-dominant hand, stretch the skin around the injection site so it is tight.
14. Holding the syringe like a dart in the dominant hand, inform the patient and quickly
plunge the needle at an angle of 90° into the skin. Aspiration is generally not required
unless injecting the vascular dorsogluteal site.
15. Depress the plunger at approximately one ml every 10 seconds, and slowly inject the
drug.
16. While withdrawing the needle, release the retracted skin at the same time to seal off the
puncture track.
17. Apply gentle pressure at the injection site, and then apply a small plaster over the
puncture site.
18. Do not recap needle. Discard all sharps into sharps container.
19. Have patient remove Buzzy® device and turn it off. Take the device and disinfect
appropriately using alcohol or another type of sterilizing wipe. Return wings to
freezer after cleaning.
20. Remove gloves and dispose correctly according to local policy, along with other nonsharps.
21. Perform hand hygiene.
22. Chart and sign medication record appropriately.
23. Evaluate for any adverse response to medication.
Derived from:
The Joanna Briggs Institute. Recommended Practice. Injection: Intramuscular. The Joanna Briggs Institute EBP Database,
JBI@Ovid.2019; JBI2138.
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APPENDIX E

